Article

Personalized Medicine for Meningiomas: Drug Screening on Tumor Organoids Exposes Therapeutic Vulnerabilities to HDAC1/2i Panobinostat

2024-12-01

Abstract excerpt

<h4>SUMMARY</h4> Managing aggressive meningiomas remains challenging due to limited treatment options besides surgical tumor removal and radiotherapy. To identify novel therapies for aggressive meningiomas, we established a multi-step drug screening workflow, focusing on targetable genes obtained from transcriptome data of highly aggressive grade 3 meningiomas. In vitro screening of 107 targeted drugs identified...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2861f10d-4b42-52d7-b173-85c5669ddc8e
DOI: 10.1101/2024.11.26.625347

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Personalized Medicine for Meningiomas: Drug Screening on Tumor Organoids Exposes Therapeutic Vulnerabilities to HDAC1/2i PanobinostatDOI 10.1101/2024.11.26.625347Read

High-Throughput Mechanistic Screening of Epigenetic Compounds for the Potential Treatment of MeningiomasSemantic proximity Read

Establishment of tumor microenvironment-preserving organoid model from patients with intracranial meningiomaSemantic proximity Read

Meningioma epigenetic grouping reveals biologic drivers and therapeutic vulnerabilitiesSemantic proximity Read

Novel Human Meningioma Organoids Recapitulate the Aggressiveness of the Initiating Cell Subpopulations Identified by ScRNA‐SeqSemantic proximity Read

Current treatment options for meningioma.Semantic proximity Read

Comprehensive analysis of TEAD inhibition in meningioma identifies MEK and mTOR inhibition as effective combination therapies against resistant linesSemantic proximity Read

Medical management of meningioma in the era of precision medicine.Semantic proximity Read

[The Potential of Personalized/Precision Medicine for Meningiomas].Semantic proximity Read

‘An <i>NF2-</i> wildtype malignant meningioma cell line for basic and translational science’Semantic proximity Read

Advances in meningioma genomics, proteomics, and epigenetics: insights into biomarker identification and targeted therapiesSemantic proximity Read

Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design.Semantic proximity Read